Trial intelligence / Profile preview

AARON: Relatlimab + Nivolumab + Azacitidine ± Venetoclax in AML

2024-514948-89-00Phase 2Completed

Sponsor: LMU Klinikum
Start: Oct 2024
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Countries: 1

Overview

Phase 2, open-label trial of relatlimab, nivolumab, azacitidine and venetoclax in acute myeloid leukemia (AML) (2 cohorts), sponsored by LMU Klinikum. Primary endpoints: Maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of relatlimab + nivolumab + azacitidine in relapsed/refractory AML (Phase I lead-in), Maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of relatlimab + nivolumab + azacitidine + venetoclax in frontline non-fit AML (Phase I lead-in) and 2 more. Started Oct 2024; status: completed.

Drugs

relatlimabnivolumabazacitidinevenetoclax

Conditions

acute myeloid leukemia (AML)

Beyond the preview

Go deeper on 2024-514948-89-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-514948-89-00.